Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Stability Analysis of Proteins for the Biopharmaceutical Industry

The biggest class of biopharmaceuticals on the market is monoclonal antibodies (mAb) and their specific binding nature provides an opportunity to use them to modulate pharmaceutically-relevant molecule activity to control or prevent disease.

A key difference between traditional small molecule pharmaceuticals and biopharmaceuticals is that the latter needs to be processed and delivered in liquid form. Proteins are notoriously unstable in solutions, so approaches need to be developed where these biotherapeutic molecules can be manufactured and stored for long periods in solution without degrading. This is where protein stability has proved invaluable in the development and manufacture of biotherapeutics.

Download to find out more.

Stability Analysis of Proteins for the Biopharmaceutical Industry

For Free, instant access, click below.

Download Whitepaper

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.

Thank You

Your white paper is now downloading... Click here if the download does not begin.

Go Top